| ID | 1115 |
| Name of the vaccine | Vivotif |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | Over 6 years |
| Description of the vaccine | Contains the attenuated strain Salmonella typhi Ty21a. |
| Name of the manufacturer | Emergent Travel Health Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | 1989 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | In Alexandria, Egypt - 95% decrease in the incidence of typhoid fever. In Santiago, Chile - vaccine efficacy was 29% for the single dose schedule and 59% for the 2-dose schedule. |
| Vaccine formulation | Capsule |
| Dosage | All 4 doses of vaccine be taken at the alternate day interval. Re-immunization dose of 4 vaccine capsules taken on alternate days be given every 5 years. |
| Mechanism of action | Humoral anti-S. typhi LPS antibody response. |
| Route of administration | Oral |
| Indications | Selective immunization recommended for travellers or people in close contact with the bacteria. |
| Export | Distributed by - Emergent Travel Health Inc., USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Abdominal pain, nausea, headache, fever, diarrhoea, vomiting and skin rash. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.drugs.com/pro/vivotif.html |
| Other name | NA |
| Additional Links | NA
|